'A watershed moment': A pancreatic cancer drug is set to transform treatment
- The Food and Drug Administration has fast-tracked daraxonrasib for advanced metastatic pancreatic cancer and authorized an expanded-access program allowing Revolution Medicines to provide the drug to patients outside clinical trials.
- More than 90% of pancreatic cancers involve a RAS gene mutation long considered "undruggable" after years of failed attempts to block it. Daraxonrasib solves this by acting as a "molecular glue" to target the protein.
- Early Phase 3 clinical trial data showed patients receiving daraxonrasib plus chemotherapy achieved overall survival of 13.2 months, compared to 6.7 months for chemotherapy alone.
- While trials revealed side effects including blistering rashes and mouth sores severe in about 30% of patients, Dr. Brian Wolpin of the Dana-Farber Cancer Institute said the drug is "much more tolerable than chemo."
- Researchers are currently studying daraxonrasib for other RAS-mutated cancers including colorectal and lung, positioning the drug as a potential breakthrough across multiple cancer types.
10 Articles
10 Articles
Targeted RAS inhibitor shows promise against pancreatic cancer mutations
The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
Safety Data on the Novel Pancreatic Cancer Drug Available by Early Access
(MedPage Today) -- The investigational drug daraxonrasib, now available through an early access program, demonstrated promising efficacy in previously treated pancreatic ductal adenocarcinoma (PDAC) and was associated with high-grade adverse events...
'A watershed moment': A pancreatic cancer drug is set to transform treatment
An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
